Abivax Secures Cash For Ulcerative Colitis Drug But Much More Needed
Obefazimod Moves Into Costly Phase III
The French biotech is pleased to have raised nearly €50m considering the "currently very challenging financing environment," but it will need to find €150m more to complete last-stage trials of obefazimod in ulcerative colitis.
